stella
beta
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma — Stella
Home
/
Pancreatic Ductal Adenocarcinoma
/
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
View on ClinicalTrials.gov
Recruiting
Back to Pancreatic Ductal Adenocarcinoma trials
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Trial locations
(2 sites)
United States
Roswell Park Comprehensive Cancer Center, Buffalo, New York
Good Samaritan University Hospital, West Islip, New York